Tissue-type plasminogen activator (t-PA) is a widely used thrombolytic agent for treating acute myocardial infarction. Some previous studies suggest that t-PA benefits the heart independently of lysing coronary artery thrombi. The purpose of this study was to determine whether t-PA directly affects infarct size independently of lysing coronary thrombi, alfects the no-reflow phenomenon, and exacerbates intramyocardial hemorrhage. We used a canine model of 2 hours of occlusion of the left anterior descending coronary artery followed by 4 hours of reperfusion. treating acute myocardial infarction and despite its well-recognized ability to lyse thrombi in proximal coronary arteries, few data are available concerning the effect of t-PA on the myocardium and microvasculature of the heart. Currently, two studies in the literature suggest that the beneficial effects of t-PA on the heart may occur independent of its ability to lyse proximal epicardial coronary artery thrombi.8,9
T he 1980s have become the era of coronary artery reperfusion for the treatment of acute myocardial infarction. Several studies have shown that timely thrombolytic therapy decreases chest pain, decreases mortality, improves left ventricular function, and reduces infarct size.1-5 Tissuetype plasminogen activator (t-PA) has emerged as one of the most popular thrombolytic agents in the United States, and it has been more efficacious than streptokinase in lysing coronary thrombi. 6 Although t-PA has less effect on the systemic clotting system, the clinical incidence of bleeding complications with t-PA does not appear to be less than with streptokinase.7 Despite the wide use of t-PA for treating acute myocardial infarction and despite its well-recognized ability to lyse thrombi in proximal coronary arteries, few data are available concerning the effect of t-PA on the myocardium and microvasculature of the heart. Currently, two studies in the literature suggest that the beneficial effects of t-PA on the heart may occur independent of its ability to lyse proximal epicardial coronary artery thrombi. 8, 9 In one study,8 a coronary artery was occluded with a clamp (mechanical rather than thrombotic occlusion), and t-PA then was administered during the reperfusion phase (release of the clamp). The extent of necrosis in the t-PA group was dramatically reduced, suggesting that t-PA has a direct beneficial effect on the myocardium independent of its ability to lyse proximal coronary thrombi. The investigators suggested three possible mechanisms: 1) induction of vasodilation of coronary arteries, 2) membrane stabilization resulting in the reduced release of autolytic enzymes, and 3) thrombolysis of microthrombi with reduction of no-reflow. A recently reported study in dogs showed similar results.9
Coronary artery reperfusion may also result in hemorrhagic myocardial infarction.10,11 Thrombolytic agents potentially could exacerbate this hemorrhage into the infarct and perhaps could even result in hemorrhage into nonnecrotic peri-infarct border zones jeopardizing viable myocytes. The purpose of this study was threefold: 1) to determine whether t-PA reduces infarct size independently of its ability to lyse proximal coronary thrombi in a mechanical model of 2 hours of coronary occlusion and 4 hours of reperfusion in the anesthetized dog, 2) to determine whether t-PA exacerbates intramyocardial hemorrhage during coronary reperfusion, and 3) to determine whether t-PA affects the noreflow phenomenon, assessed with radioactive microspheres.12,13
Two protocols were used in this study. In the first protocol, we used a low dose of t-PA (lower than doses administered to humans but a dose that has been shown to be thrombolytic in the canine model14); in the second protocol, we used a high dose of t-PA (equivalent to doses administered to patients).
Methods Protocol 1 Mongrel dogs of either sex were anesthetized with intravenous sodium pentobarbital (35 mg/kg), intubated, and ventilated with a Harvard respirator (South Natick, Massachusetts). Small amounts of additional sodium pentobarbital were administered throughout the experiment as needed to ensure adequate anesthesia. A cannula was positioned into the left carotid artery for monitoring arterial blood pressure and for withdrawing reference blood samples for regional myocardial blood flow (RMBF) measurements. A second catheter was placed into the left jugular vein for administration of fluids and drugs. A left thoracotomy was performed at the fifth left intercostal space, the pericardium was incised, and the left anterior descending coronary artery was then isolated proximal to the first major diagonal branch. A third cannula was positioned in the left atrium for injection of radioactive microspheres for RMBF measurement. After baseline hemodynamic levels were measured, the left anterior descending coronary artery was occluded with a Schwartz atraumatic vascular clamp (Pilling, Ft. Washington, Pennsylvania). RMBF was determined 25 minutes after occlusion (after occlusion, before treatment) with radioactive microspheres.13,14 Thirty minutes after coronary artery occlusion, the surviving dogs were randomized to receive either commercially available t-PA (Activase;1,000 IU/kg/ min; 0.21 mg/kg; Genentech, San Francisco, California) or saline infused intravenously for a total of 2 hours. This administration protocol was followed to simulate the clinical situation in which t-PA is on hand for a period of time before reperfusion. This dose range of t-PA previously has been shown to be thrombolytic in the canine model.12 At 105 minutes after occlusion, RMBF was determined a second time (after occlusion, after treatment). At 120 minutes after occlusion, the coronary artery was reperfused by abrupt removal of the clamp. At 5.5 hours after occlusion, RMBF was determined a third time (after reperfusion). At 6 hours after occlusion (4 hours after reperfusion), the left anterior descending coronary artery was reoccluded briefly at the same site as the initial occlusion, and Monastral blue dye (0.25 ml/kg, CIBA-GEIGY, Hawthorne, New York) was injected into the left atrium to determine in vivo area at risk. The anesthetized dogs were killed by intracardiac injection of potassium chloride. The heart was excised, the atria and right ventricle were removed, and the left ventricle was sectioned from apex to base into 4-5-mm transverse sections. The heart sections were weighed, and the nonstained zone (area at risk) was traced onto acetate sheets and photographed. The left ventricular sections were then incubated in triphenyltetrazolium chloride (TIC) at 350 C for 10 minutes to delineate the area of necrosis by methods described previously.15-17 The area of necrosis was traced onto acetate sheets and photographed. Area of necrosis and nrsk were corrected for weight of the left ventricular slices and The area of necrosis for this slice was obtained by using the opposing block face of the adjacent heart slice as a reference. 10 In protocols 1 and 2, any dog developing ventricular fibrillation was excluded from the study. In addition, any dogs with pretreatment endocardial blood flow during coronary occlusion greater than 0.40 mV min/g (high flow) or with risk zones of less than 10% of the left ventricle were excluded because such risk zones result in little if any necrosis in this model. Hemodynamic data are shown in Table 1 . No differences occurred in heart rate and systolic and diastolic blood pressure between the two groups at anytime throughout the protocol.
RMBF data were available in seven of eight dogs receiving saline and in eight of eight dogs receiving t-PA. As expected, RMBF analysis showed that RMBF was depressed in the area at risk during coronary occlusion (Table 2) . Collateral blood flow was lower in the subendocardium and higher in the subepicardium. t-PA had no effect on RMBF during coronary occlusion. RMBF levels after reperfusion improved but did not return to normal. RMBF in the endocardium of the area at risk was depressed at 0.37 ml/min/g tissue in saline and t-PA groups, whereas flow in the nonischemic zone averaged 0.77 0.80 ml/min/g. This continued reduction of flow was probably due to the no-reflow phenomenon.
Photographs that were adequate for determining hemorrhagic score were available in seven of eight dogs receiving saline and low-dose t-PA. The extent of gross hemorrhage tended to be larger in the t-PA group (score= 1.1 + 0.4) compared with the saline group (0.6±0.3) although this was not statistically significant. The hemorrhage did not extend beyond the zone of infarction (Figure 2) .
Histologic evaluation (n-16) of the area at risk revealed the presence of contraction bands typical of irreversibly injured myocytes that have been subject to reperfusion. The extent of microscopic hemorrhage was variable but tended to be more prominent in the t-PA group. Nevertheless, we did not observe zones of microscopic hemorrhage outside of the zone of contraction band necrosis. Hemorrhage was confined to within the area of contraction band necrosis in both groups. Neutrophil infiltration was prominent, especially in the t-PA group. Neutrophils were present both within and peripheral to zones of contraction band necrosis (Figure 3 ). Forty dogs were entered into protocol 2. Twentyfour dogs developed ventricular fibrillation (in most cases, before randomization), three had risk zones less than 10% of the left ventricle, and one dog had high pretreatment endocardial flow during occlu-sion. Six dogs were successfully randomized to receive high-dose t-PA and six to saline.
The area at risk was similar in both groups at 17 ±2% of the left ventricle in the control group and 21±2% of the left ventricle in the t-PA group. The extent of necrosis was similar in control and t-PA groups whether expressed as a percentage of the left ventricle (8±2% vs. 10±3%) or as a percentage of area at risk (46±12% vs. 44±12% in control vs. t-PA groups, respectively, p=NS) (Figure 4) . Figure 4B shows the relation of area of necrosis to area at risk as a function of ischemic epicardial blood flow within the risk zone. Thus, high-dose t-PA also did not reduce infarct size more than did reperfusion alone.
Hemodynamic data are shown in Table 3 . Hemodynamic data were unavailable in one t-PA-treated dog. No differences in hemodynamic values were found between groups throughout the study. Regional myocardial blood flow data are shown in Table 4 . Endocardial blood flow was depressed more than was epicardial blood flow during coronary occlusion. With reperfusion, endocardial blood flow remained depressed, which is consistent with a no-reflow phenomenon. t-PA did not affect RMBF either during coronary occlusion or after reperfusion.
Photographs that were adequate for determining hemorrhagic score were available in all dogs and 5). There was no difference in the gross hemorrhagic score between the control (1.3±0.5) and the high-dose t-PA group (1.5±0.4).
Histologic analysis (n=12) revealed hemorrhage in both groups ( Figure 6 ). No difference was found in the extent of hemorrhage between groups, and again, hemorrhage tended to be confined to zones of contraction band necrosis and did not extend beyond these areas. Neutrophil infiltration was extensive in both groups ( Figure 6 ). Neutrophils often appeared to be filling vessels and were in the interstitium as well. No noticeable difference was found in the extent of neutrophil infiltration between groups.
Myocardial hemoglobin concentration in nonischemic tissue was 6.5±0.5 ,ug/mg in the control and 7.0±1.0 ,ug/mg in the high-dose t-PA group. Within the risk zone, hemoglobin levels were increased in both groups: 16.3±4.5 pg/mg in dogs receiving saline (6 dogs) and 11.6±2.6 gg/mg in dogs receiving t-PA (6 dogs). Hemoglobin levels between control and t-PA groups did not differ. Neither the gross hemorrhagic score, the microscopic, nor the hemoglobin analysis suggested that t-PA exacerbated reperfusion-induced hemorrhage.
A significant correlation was found between the degree of hemorrhage assessed by intramyocardial hemoglobin concentration and area of necrosis (AN), expressed as a percentage of the area at risk (AR) [Hemoglobin = 26.6(AN/AR)+2.0; r=0.85; Figure  7A ]. Also, a moderate negative correlation was found between extent of hemorrhage and subepicardial coronary blood flow during occlusion (r= -0.61; Figure 7B), and a negative correlation was found between extent of hemorrhage and subendocardial blood flow after 4 hours of reperfusion (r= -0.66).
The degree of hemorrhage did not significantly correlate with heart rate, systolic blood pressure, rate-pressure product, or area at risk.
Discussion t-PA has become a widely used agent for the treatment of acute myocardial infarction. There is no question that it is efficacious in lysing proximal epicardial coronary thrombi and restoring vessel patency.6 Coronary reperfusion, when instituted within a few hours of coronary occlusion, reduces infarct size.19,20 Early investigators had assumed that any beneficial effect that t-PA had on the myocardium was through its ability to lyse proximal thrombi and to initiate reperfusion. However, a study by Darius et a18 suggested that t-PA may reduce the extent of myocardial necrosis by a mechanism that is independent of its ability to lyse proximal thrombi. They used a melanoma cellderived tissue-type plasminogen activator in a cat model of 2 hours of coronary occlusion followed by myocardium in the anesthetized canine model of mechanical coronary occlusion followed by reperfusion. We used two doses of t-PA. In one protocol, a low dose of t-PA was used that previously had been shown to be thrombolytic in a canine model.14 We also used a higher dose of t-PA that is equivalent to that administered to patients (equivalent to 100 mg given to a 70 kg person). We observed no effect with either dosage regimens on the extent of necrosis whether expressed as a percentage of the left ventricle or normalized to the size of the area at risk.
Thus, our results suggest that any beneficial effects of t-PA result from its ability to lyse proximal thrombi rather than to some direct protective effect on the myocardial cells. Our results also do not support the hypothesis that t-PA's mechanism of action is by dissolution of microthrombi that results in improved perfusion of the coronary microvasculature. Reperfusion myocardial blood flows were depressed, especially in the subendocardium. This reduction in flow was most likely related to the no-reflow phenomenon.23 Neither low-nor highdose t-PA improved reperfusion regional blood flows compared with control groups, which suggests that t-PA had no effect on microvascular perfusion or no-reflow phenomenon. We observed similar results in a previous study with streptokinase.10 Streptokinase, in a mechanical model of coronary occlusion and reperfusion, failed to reduce myocardial infarct size. Therefore, the benefits to myocardium of both streptokinase and t-PA are likely due to epicardial coronary artery recanalization rather than to a direct effect on myocardial cells or the microvasculature.
Some technical differences do exist between the negative findings of the present study and the positive findings of the two previous studies that may explain the different outcomes. The study by Darius et a18 was in a cat model; therefore, species differences may account for the different results. Also, they used a melanoma cell-derived tissue-type plasminogen activator that may have actions different from the single-stranded, commercially available (Genentech) t-PA that was used in the present study. Also, a recent study from the same laboratory24 failed to show a benefit of t-PA on infarct size. However, a combination of t-PA and a thromboxane synthetase inhibitor potentiated myocardial salvage in this study. The reason for a failure of t-PA alone to reduce infarct size in their second study is not clear. Collateral blood flow was not measured in the study by Darius et al. 8 Conceivably, a higher baseline collateral blood flow in several cats in the t-PA group may have contributed to an apparent reduction in infarct size. Berger et a19 induced reperfusion by using a technique different from the one used in the present study. They gradually released the snare to prevent hyperemia, whereas we simply removed the atraumatic vascular clamp around the left anterior descending coronary artery. It is unknown whether differences in the t-PA preparation (Burroughs Wellcome) used in the study by Berger et a19 and the t-PA preparation (Genentech) used in our study could explain the different outcomes.
Our tized animal preparation was used, we cannot rule out the possibility that drug-to-drug interaction somehow inhibited a positive effect. However, anesthesia alone probably could not explain the negative results of our study because anesthetized preparations were also used in the two previous studies that had positive results with t-PA.h 9 Hemorrhage into the myocardium is a complication of coronary reperfusion. This phenomenon has been documented by gross pathologic study, microscopy, and measurement of myocardial hemoglobin levels. 10'11X25 Probably, the vascular endothelium becomes damaged during ischemia. During reperfusion, the vascular endothelium can no longer contain the influx of blood, and intramyocardial hemorrhage occurs. Whether hemorrhage after reperfusion is deleterious remains controversial. If the hemorrhage within the infarct were to infiltrate the viable myocardium, then the pressure exerted by this hemorrhage in the interstitium could jeopardize blood supply to the still viable myocytes. In the experimental canine model of coronary occlusion followed by reperfusion, including the present study, we have not observed hemorrhage infiltrating areas beyond the myocardium already damaged. Although hemorrhage theoretically could impede the healing process of reperfused myocardium, we have not observed long-term deleterious consequences of scar formation in reperfused infarcts.'1 Although there was a nonsignificant trend for increased hemorrhage in the low-dose t-PA group compared with the control group, this was not observed in the high-dose t-PA group. In the high-dose study (which used a dose approximately equivalent to the dose currently used in humans), hemorrhage was extensive but equally severe in control and t-PA groups. Similar results previously were reported by our laboratory with streptokinase.10
A striking histologic feature in the reperfused myocardium of control and t-PA groups in both protocols was the prominent influx of neutrophils. This finding suggests that reperfusion of infarcts alters the development of the inflammatory response. Although the classic studies of pathology of infarcts show peak neutrophil infiltration at approximately 48 hours after coronary occlusion,26 reperfusion appears to speed this initial inflammatory response. Thus, after 2 hours of coronary occlusion and only 4 hours of reperfusion, neutrophil infiltration was prominent. Large sheets of neutrophils were in the interstitium and appeared to fill some capillaries. Some investigators have postulated that these neu- 
